This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frank, T. S. Articles by Critchfield, G. C. Search for Related Content PubMed PubMed Citation Articles by Frank, T. S. Articles by Critchfield, G. C. Social Bookmarking                            What's this?

Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals

From Myriad Genetic Laboratories and Myriad Genetics, Inc, Salt Lake City, UT.

Address reprint requests to Thomas S. Frank, MD, Department of Medical Services, Myriad Genetic Laboratories, 320 Wakara Way, Salt Lake City, UT 84108; email: tfrank{at}myriad.com

PURPOSE: To assess the characteristics that correlate best with the presence of mutations in BRCA1 and BRCA2 in individuals tested in a clinical setting.

PATIENTS AND METHODS: The results of 10,000 consecutive gene sequence analyses performed to identify mutations anywhere in the BRCA1 and BRCA2 genes (7,461 analyses) or for three specific Ashkenazi Jewish founder mutations (2,539 analyses) were correlated with personal and family history of cancer, ancestry, invasive versus noninvasive breast neoplasia, and sex.

RESULTS: Mutations were identified in 1,720 (17.2%) of the 10,000 individuals tested, including 968 (20%) of 4,843 women with breast cancer and 281 (34%) of 824 with ovarian cancer, and the prevalence of mutations was correlated with specific features of the personal and family histories of the individuals tested. Mutations were as prevalent in high-risk women of African (25 [19%] of 133) and other non-Ashkenazi ancestries as those of European ancestry (712 [16%] of 4379) and were significantly less prevalent in women diagnosed before 50 years of age with ductal carcinoma in situ than with invasive breast cancer (13% v 24%, P = .0007). Of the 74 mutations identified in individuals of Ashkenazi ancestry through full sequence analysis of both BRCA1 and BRCA2, 16 (21.6%) were nonfounder mutations, including seven in BRCA1 and nine in BRCA2. Twenty-one (28%) of 76 men with breast cancer carried mutations, of which more than one third occurred in BRCA1.

CONCLUSION: Specific features of personal and family history can be used to assess the likelihood of identifying a mutation in BRCA1 or BRCA2 in individuals tested in a clinical setting.

T.S.F, A.M.D., M.H., B.E.W, B.L., K.L.G., T.S., and G.C.C. are employees of Myriad Genetic Laboratories, which receives revenue for its analysis of BRCA1 and BRCA2. J.E.R., S.V.T., and D.R.P. are employees of Myriad Genetics, Inc, which is the parent company of Myriad Genetic Laboratories.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. W. Kurian, L. A. McClure, E. M. John, P. L. Horn-Ross, J. M. Ford, and C. A. Clarke Second Primary Breast Cancer Occurrence According to Hormone Receptor Status J Natl Cancer Inst, July 9, 2009; (2009) djp181v1. [Abstract] [Full Text] [PDF]

				P. Pasanisi, G. Hedelin, J. Berrino, J. Chang-Claude, S. Hermann, M. Steel, N. Haites, J. Hart, R. Peled, L. Gafa, et al. Oral Contraceptive Use and BRCA Penetrance: A Case-Only Study Cancer Epidemiol. Biomarkers Prev., July 1, 2009; 18(7): 2107 - 2113. [Abstract] [Full Text] [PDF]

				M. Pensabene, I. Spagnoletti, I. Capuano, C. Condello, S. Pepe, A. Contegiacomo, G. Lombardi, G. Bevilacqua, and M. A. Caligo Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling Ann. Onc., May 1, 2009; 20(5): 874 - 878. [Abstract] [Full Text] [PDF]

				S. W. Gray, C. O'Grady, L. Karp, D. Smith, J. S. Schwartz, R. C. Hornik, and K. Armstrong Risk Information Exposure and Direct-to-Consumer Genetic Testing for BRCA Mutations among Women with a Personal or Family History of Breast or Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1303 - 1311. [Abstract] [Full Text] [PDF]

				A. W. Kurian, G. D. Gong, E. M. John, A. Miron, A. Felberg, A. I. Phipps, D. W. West, and A. S. Whittemore Performance of Prediction Models for BRCA Mutation Carriage in Three Racial/Ethnic Groups: Findings from the Northern California Breast Cancer Family Registry Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1084 - 1091. [Abstract] [Full Text] [PDF]

				D. Huo, R. T. Senie, M. Daly, S. S. Buys, S. Cummings, J. Ogutha, K. Hope, and O. I. Olopade Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States J. Clin. Oncol., March 10, 2009; 27(8): 1184 - 1190. [Abstract] [Full Text] [PDF]

				B. Arun, K. J. Vogel, A. Lopez, M. Hernandez, D. Atchley, K. R. Broglio, C. I. Amos, F. Meric-Bernstam, H. Kuerer, G. N. Hortobagyi, et al. High Prevalence of Preinvasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers Cancer Prevention Research, February 1, 2009; 2(2): 122 - 127. [Abstract] [Full Text] [PDF]

				J. E. Garber BRCA1/2-Associated and Sporadic Breast Cancers: Fellow Travelers or Not? Cancer Prevention Research, February 1, 2009; 2(2): 100 - 103. [Full Text] [PDF]

				O. I. Olopade, T. A. Grushko, R. Nanda, and D. Huo Advances in Breast Cancer: Pathways to Personalized Medicine Clin. Cancer Res., December 15, 2008; 14(24): 7988 - 7999. [Abstract] [Full Text] [PDF]

				P. L. Mai, V. I. Lagos, M. R. Palomares, and J. N. Weitzel Contralateral Risk-Reducing Mastectomy in Young Breast Cancer Patients with and without Genetic Cancer Risk Assessment Ann. Surg. Oncol., December 1, 2008; 15(12): 3415 - 3421. [Abstract] [Full Text] [PDF]

				A. D. Spearman, K. Sweet, X.-P. Zhou, J. McLennan, F. J. Couch, and A. E. Toland Clinically Applicable Models to Characterize BRCA1 and BRCA2 Variants of Uncertain Significance J. Clin. Oncol., November 20, 2008; 26(33): 5393 - 5400. [Abstract] [Full Text] [PDF]

				A. W. Kurian, G. D. Gong, N. M. Chun, M. A. Mills, A. D. Staton, K. E. Kingham, B. B. Crawford, R. Lee, S. Chan, S. S. Donlon, et al. Performance of BRCA1/2 Mutation Prediction Models in Asian Americans J. Clin. Oncol., October 10, 2008; 26(29): 4752 - 4758. [Abstract] [Full Text] [PDF]

				D S P Tan, C Marchio, and J S Reis-Filho Hereditary breast cancer: from molecular pathology to tailored therapies J. Clin. Pathol., October 1, 2008; 61(10): 1073 - 1082. [Abstract] [Full Text] [PDF]

				D. C. Allain Genetic Counseling and Testing for Common Hereditary Breast Cancer Syndromes: A Paper from the 2007 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2008; 10(5): 383 - 395. [Abstract] [Full Text] [PDF]

				M. D. Palma, S. M. Domchek, J. Stopfer, J. Erlichman, J. D. Siegfried, J. Tigges-Cardwell, B. A. Mason, T. R. Rebbeck, and K. L. Nathanson The Relative Contribution of Point Mutations and Genomic Rearrangements in BRCA1 and BRCA2 in High-Risk Breast Cancer Families Cancer Res., September 1, 2008; 68(17): 7006 - 7014. [Abstract] [Full Text] [PDF]

				T. Hucl, C. Rago, E. Gallmeier, J. R. Brody, M. Gorospe, and S. E. Kern A Syngeneic Variance Library for Functional Annotation of Human Variation: Application to BRCA2 Cancer Res., July 1, 2008; 68(13): 5023 - 5030. [Abstract] [Full Text] [PDF]

				A C Antoniou, R Hardy, L Walker, D G Evans, A Shenton, R Eeles, S Shanley, G Pichert, L Izatt, S Rose, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics J. Med. Genet., July 1, 2008; 45(7): 425 - 431. [Abstract] [Full Text] [PDF]

				S. Domchek and B. L. Weber Genetic Variants of Uncertain Significance: Flies in the Ointment J. Clin. Oncol., January 1, 2008; 26(1): 16 - 17. [Full Text] [PDF]

				A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, and S. Sadetzki Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer J. Clin. Oncol., January 1, 2008; 26(1): 20 - 25. [Abstract] [Full Text] [PDF]

				J. Balmana, E. W. Steyerberg, and S. Syngal Risk Quantification for Carrying Mutations in Lynch Syndrome Genes ASCO Educational Book, January 1, 2008; 2008(1): 59 - 64. [Abstract] [Full Text] [PDF]

				E. M. John, A. Miron, G. Gong, A. I. Phipps, A. Felberg, F. P. Li, D. W. West, and A. S. Whittemore Prevalence of Pathogenic BRCA1 Mutation Carriers in 5 US Racial/Ethnic Groups JAMA, December 26, 2007; 298(24): 2869 - 2876. [Abstract] [Full Text] [PDF]

				D. Huo and O. I. Olopade Genetic Testing in Diverse Populations: Are Researchers Doing Enough to Get Out the Correct Message? JAMA, December 26, 2007; 298(24): 2910 - 2911. [Full Text] [PDF]

				Y. C. Tai, S. Domchek, G. Parmigiani, and S. Chen Breast Cancer Risk Among Male BRCA1 and BRCA2 Mutation Carriers J Natl Cancer Inst, December 5, 2007; 99(23): 1811 - 1814. [Abstract] [Full Text] [PDF]

				K. J. Vogel, D. P. Atchley, J. Erlichman, K. R. Broglio, K. J. Ready, V. Valero, C. I. Amos, G. N. Hortobagyi, K. H. Lu, and B. Arun BRCA1 and BRCA2 Genetic Testing in Hispanic Patients: Mutation Prevalence and Evaluation of the BRCAPRO Risk Assessment Model J. Clin. Oncol., October 10, 2007; 25(29): 4635 - 4641. [Abstract] [Full Text] [PDF]

				G. Parmigiani, S. Chen, E. S. Iversen Jr, T. M. Friebel, D. M. Finkelstein, H. Anton-Culver, A. Ziogas, B. L. Weber, A. Eisen, K. E. Malone, et al. Validity of Models for Predicting BRCA1 and BRCA2 Mutations Ann Intern Med, October 2, 2007; 147(7): 441 - 450. [Abstract] [Full Text] [PDF]

				S. M. Domchek and A. Antoniou Cancer Risk Models: Translating Family History into Clinical Management Ann Intern Med, October 2, 2007; 147(7): 515 - 517. [Full Text] [PDF]

				J. N. Weitzel, V. I. Lagos, J. S. Herzog, T. Judkins, B. Hendrickson, J. S. Ho, C. N. Ricker, K. J. Lowstuter, K. R. Blazer, G. Tomlinson, et al. Evidence for Common Ancestral Origin of a Recurring BRCA1 Genomic Rearrangement Identified in High-Risk Hispanic Families Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1615 - 1620. [Abstract] [Full Text] [PDF]

				K. L. Smith, M. Adank, N. Kauff, K. Lafaro, J. Boyd, J. B. Lee, C. Hudis, K. Offit, and M. Robson BRCA Mutations in Women with Ductal Carcinoma In situ Clin. Cancer Res., July 15, 2007; 13(14): 4306 - 4310. [Abstract] [Full Text] [PDF]

				M. Robson and K. Offit Management of an Inherited Predisposition to Breast Cancer N. Engl. J. Med., July 12, 2007; 357(2): 154 - 162. [Full Text] [PDF]

				C. Capalbo, A. Buffone, A. Vestri, E. Ricevuto, C. Rinaldi, M. Zani, S. Ferraro, L. Frati, I. Screpanti, A. Gulino, et al. Does the Search for Large Genomic Rearrangements Impact BRCAPRO Carrier Prediction? J. Clin. Oncol., June 20, 2007; 25(18): 2632 - 2634. [Full Text] [PDF]

				J. N. Weitzel, V. I. Lagos, C. A. Cullinane, P. J. Gambol, J. O. Culver, K. R. Blazer, M. R. Palomares, K. J. Lowstuter, and D. J. MacDonald Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer JAMA, June 20, 2007; 297(23): 2587 - 2595. [Abstract] [Full Text] [PDF]

				N. D. Kauff and K. Offit Modeling Genetic Risk of Breast Cancer JAMA, June 20, 2007; 297(23): 2637 - 2639. [Full Text] [PDF]

				M. Tischkowitz, B. Xia, N. Sabbaghian, J. S. Reis-Filho, N. Hamel, G. Li, E. H. van Beers, L. Li, T. Khalil, L. A. Quenneville, et al. Analysis of PALB2/FANCN-associated breast cancer families PNAS, April 17, 2007; 104(16): 6788 - 6793. [Abstract] [Full Text] [PDF]

				E. S. Hwang, J. L. McLennan, D. H. Moore, B. B. Crawford, L. J. Esserman, and J. L. Ziegler Ductal Carcinoma In Situ in BRCA Mutation Carriers J. Clin. Oncol., February 20, 2007; 25(6): 642 - 647. [Abstract] [Full Text] [PDF]

				K. Brewster, E. P. Wileyto, L. Kessler, A. Collier, B. Weathers, J. E. Stopfer, S. Domchek, and C. H. Halbert Sociocultural Predictors of Breast Cancer Risk Perceptions in African American Breast Cancer Survivors Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 244 - 248. [Abstract] [Full Text] [PDF]

				I. Agalliu, E. M. Kwon, D. Zadory, L. McIntosh, J. Thompson, J. L. Stanford, and E. A. Ostrander Germline Mutations in the BRCA2 Gene and Susceptibility to Hereditary Prostate Cancer Clin. Cancer Res., February 1, 2007; 13(3): 839 - 843. [Abstract] [Full Text] [PDF]

				A Smith, A Moran, M C Boyd, M Bulman, A Shenton, L Smith, R Iddenden, E R Woodward, F Lalloo, E R Maher, et al. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening J. Med. Genet., January 1, 2007; 44(1): 10 - 15. [Abstract] [Full Text] [PDF]

				T. Walsh, S. Casadei, E. Swisher, S. M. Stray, J. Higgins, K. C. Roach, M. K. Lee, and M.-C. King Mutations in Families at High Risk for Breast Cancer--Reply JAMA, November 1, 2006; 296(17): 2091 - 2092. [Full Text] [PDF]

				K. E. Malone, J. R. Daling, D. R. Doody, L. Hsu, L. Bernstein, R. J. Coates, P. A. Marchbanks, M. S. Simon, J. A. McDonald, S. A. Norman, et al. Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years Cancer Res., August 15, 2006; 66(16): 8297 - 8308. [Abstract] [Full Text] [PDF]

				L. J. Pierce, A. M. Levin, T. R. Rebbeck, M. A. Ben-David, E. Friedman, L. J. Solin, E. E. Harris, D. K. Gaffney, B. G. Haffty, L. A. Dawson, et al. Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in BRCA1/2-Associated Stage I/II Breast Cancer J. Clin. Oncol., June 1, 2006; 24(16): 2437 - 2443. [Abstract] [Full Text] [PDF]

				M. J. Hall and O. I. Olopade Disparities in Genetic Testing: Thinking Outside the BRCA Box J. Clin. Oncol., May 10, 2006; 24(14): 2197 - 2203. [Abstract] [Full Text] [PDF]

				S. T. Vadaparampil, L. Wideroff, N. Breen, and E. Trapido The Impact of Acculturation on Awareness of Genetic Testing for Increased Cancer Risk among Hispanics in the Year 2000 National Health Interview Survey. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 618 - 623. [Abstract] [Full Text] [PDF]

				S V Tavtigian, A M Deffenbaugh, L Yin, T Judkins, T Scholl, P B Samollow, D de Silva, A Zharkikh, and A Thomas Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral J. Med. Genet., April 1, 2006; 43(4): 295 - 305. [Abstract] [Full Text] [PDF]

				A. N.A. Monteiro and F. J. Couch Cancer Risk Assessment at the Atomic Level Cancer Res., February 15, 2006; 66(4): 1897 - 1899. [Abstract] [Full Text] [PDF]

				P. A. James, R. Doherty, M. Harris, B. N. Mukesh, A. Milner, M.-A. Young, and C. Scott Optimal Selection of Individuals for BRCA Mutation Testing: A Comparison of Available Methods J. Clin. Oncol., February 1, 2006; 24(4): 707 - 715. [Abstract] [Full Text] [PDF]

				C. H. Barcenas, G.M. M. Hosain, B. Arun, J. Zong, X. Zhou, J. Chen, J. M. Cortada, G. B. Mills, G. E. Tomlinson, A. R. Miller, et al. Assessing BRCA Carrier Probabilities in Extended Families J. Clin. Oncol., January 20, 2006; 24(3): 354 - 360. [Abstract] [Full Text] [PDF]

				C. H. Halbert, K. Brewster, A. Collier, C. Smith, L. Kessler, B. Weathers, J. E. Stopfer, S. Domchek, and E. P. Wileyto Recruiting African American Women to Participate in Hereditary Breast Cancer Research J. Clin. Oncol., November 1, 2005; 23(31): 7967 - 7973. [Abstract] [Full Text] [PDF]

				R. Nanda, L. P. Schumm, S. Cummings, J. D. Fackenthal, L. Sveen, F. Ademuyiwa, M. Cobleigh, L. Esserman, N. M. Lindor, S. L. Neuhausen, et al. Genetic Testing in an Ethnically Diverse Cohort of High-Risk Women: A Comparative Analysis of BRCA1 and BRCA2 Mutations in American Families of European and African Ancestry JAMA, October 19, 2005; 294(15): 1925 - 1933. [Abstract] [Full Text] [PDF]

				N. D. Kauff, N. Mitra, M. E. Robson, K. E. Hurley, S. Chuai, D. Goldfrank, E. Wadsworth, J. Lee, T. Cigler, P. I. Borgen, et al. Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families J Natl Cancer Inst, September 21, 2005; 97(18): 1382 - 1384. [Abstract] [Full Text] [PDF]

				U.S. Preventive Services Task Force* Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement Ann Intern Med, September 6, 2005; 143(5): 355 - 361. [Abstract] [Full Text] [PDF]

				H. D. Nelson, L. H. Huffman, R. Fu, and E. L. Harris Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force Ann Intern Med, September 6, 2005; 143(5): 362 - 379. [Abstract] [Full Text] [PDF]

				W. Burke Taking Family History Seriously Ann Intern Med, September 6, 2005; 143(5): 388 - 389. [Full Text] [PDF]

				S. H. Giordano A Review of the Diagnosis and Management of Male Breast Cancer Oncologist, August 1, 2005; 10(7): 471 - 479. [Abstract] [Full Text] [PDF]

				J. N. Weitzel, V. Lagos, K. R. Blazer, R. Nelson, C. Ricker, J. Herzog, C. McGuire, and S. Neuhausen Prevalence of BRCA Mutations and Founder Effect in High-Risk Hispanic Families Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1666 - 1671. [Abstract] [Full Text] [PDF]

				A. N. Freedman, D. Seminara, M. H. Gail, P. Hartge, G. A. Colditz, R. Ballard-Barbash, and R. M. Pfeiffer Cancer Risk Prediction Models: A Workshop on Development, Evaluation, and Application J Natl Cancer Inst, May 18, 2005; 97(10): 715 - 723. [Abstract] [Full Text] [PDF]

				K. Armstrong, E. Micco, A. Carney, J. Stopfer, and M. Putt Racial Differences in the Use of BRCA1/2 Testing Among Women With a Family History of Breast or Ovarian Cancer JAMA, April 13, 2005; 293(14): 1729 - 1736. [Abstract] [Full Text] [PDF]

				J D Fackenthal, L Sveen, Q Gao, E K Kohlmeir, C Adebamowo, T O Ogundiran, A A Adenipekun, R Oyesegun, O Campbell, C Rotimi, et al. Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients J. Med. Genet., March 1, 2005; 42(3): 276 - 281. [Full Text] [PDF]

				B Leegte, A H van der Hout, A M Deffenbaugh, M K Bakker, I M Mulder, A ten Berge, E P Leenders, J Wesseling, J de Hullu, N Hoogerbrugge, et al. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations J. Med. Genet., March 1, 2005; 42(3): e20 - e20. [Full Text] [PDF]

				E. B. Claus, S. Petruzella, E. Matloff, and D. Carter Prevalence of BRCA1 and BRCA2 Mutations in Women Diagnosed With Ductal Carcinoma In Situ JAMA, February 23, 2005; 293(8): 964 - 969. [Abstract] [Full Text] [PDF]

				R. L. Milne, J. A. Knight, E. M. John, G. S. Dite, R. Balbuena, A. Ziogas, I. L. Andrulis, D. W. West, F. P. Li, M. C. Southey, et al. Oral Contraceptive Use and Risk of Early-Onset Breast Cancer in Carriers and Noncarriers of BRCA1 and BRCA2 Mutations Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 350 - 356. [Abstract] [Full Text] [PDF]

				J. Lorenzo Bermejo and K. Hemminki A population-based assessment of the clustering of breast cancer in families eligible for testing of BRCA1 and BRCA2 mutations Ann. Onc., February 1, 2005; 16(2): 322 - 329. [Abstract] [Full Text] [PDF]

				B. D. Ward, B. C. Hendrickson, T. Judkins, A. M. Deffenbaugh, B. Leclair, B. E. Ward, and T. Scholl A Multi-Exonic BRCA1 Deletion Identified in Multiple Families through Single Nucleotide Polymorphism Haplotype Pair Analysis and Gene Amplification with Widely Dispersed Primer Sets J. Mol. Diagn., February 1, 2005; 7(1): 139 - 142. [Abstract] [Full Text] [PDF]

				C M Phelan, V Dapic, B Tice, R Favis, E Kwan, F Barany, S Manoukian, P Radice, R B van der Luijt, B P M van Nesselrooij, et al. Classification of BRCA1 missense variants of unknown clinical significance J. Med. Genet., February 1, 2005; 42(2): 138 - 146. [Abstract] [Full Text] [PDF]

				K. Wu, S. R. Hinson, A. Ohashi, D. Farrugia, P. Wendt, S. V. Tavtigian, A. Deffenbaugh, D. Goldgar, and F. J. Couch Functional Evaluation and Cancer Risk Assessment of BRCA2 Unclassified Variants Cancer Res., January 15, 2005; 65(2): 417 - 426. [Abstract] [Full Text] [PDF]

				J. E. Garber and K. Offit Hereditary Cancer Predisposition Syndromes J. Clin. Oncol., January 10, 2005; 23(2): 276 - 292. [Abstract] [Full Text] [PDF]

				J. R. Weiss, K. B. Moysich, and H. Swede Epidemiology of Male Breast Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 20 - 26. [Abstract] [Full Text] [PDF]

				S. A. Cannistra Cancer of the Ovary N. Engl. J. Med., December 9, 2004; 351(24): 2519 - 2529. [Full Text] [PDF]

				O. I. Oloparde Genetics in Clinical Cancer Care: A Promise Unfulfilled among Minority Populations Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1683 - 1686. [Full Text] [PDF]

				T. Pal, J. Permuth-Wey, T. Holtje, and R. Sutphen BRCA1 and BRCA2 Mutations in a Study of African American Breast Cancer Patients Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1794 - 1799. [Abstract] [Full Text] [PDF]

				C. Y. Muller, J. O. Schorge, G. E. Tomlinson, and R. Ashfaq BRCAPAP: Feasibility of Clinical BRCA Testing on Liquid-Based Cervical Cytology: Implications for Biomarker Development Cancer Epidemiol. Biomarkers Prev., September 1, 2004; 13(9): 1534 - 1537. [Abstract] [Full Text] [PDF]

				D G R Evans, D M Eccles, N Rahman, K Young, M Bulman, E Amir, A Shenton, A Howell, and F Lalloo A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO J. Med. Genet., June 1, 2004; 41(6): 474 - 480. [Abstract] [Full Text] [PDF]

				M. D. Schwartz, C. Lerman, B. Brogan, B. N. Peshkin, C. Hughes Halbert, T. DeMarco, W. Lawrence, D. Main, C. Finch, C. Magnant, et al. Impact of BRCA1/BRCA2 Counseling and Testing on Newly Diagnosed Breast Cancer Patients J. Clin. Oncol., May 15, 2004; 22(10): 1823 - 1829. [Abstract] [Full Text] [PDF]

				D. H. Choi, M. H. Lee, A. E. Bale, D. Carter, and B. G. Haffty Incidence of BRCA1 and BRCA2 Mutations in Young Korean Breast Cancer Patients J. Clin. Oncol., May 1, 2004; 22(9): 1638 - 1645. [Abstract] [Full Text] [PDF]

				T. Kirchhoff, N. D. Kauff, N. Mitra, K. Nafa, H. Huang, C. Palmer, T. Gulati, E. Wadsworth, S. Donat, M. E. Robson, et al. BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews Clin. Cancer Res., May 1, 2004; 10(9): 2918 - 2921. [Abstract] [Full Text] [PDF]

				F Marroni, P Aretini, E D'Andrea, M A Caligo, L Cortesi, A Viel, E Ricevuto, M Montagna, G Cipollini, S Ferrari, et al. Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations J. Med. Genet., April 1, 2004; 41(4): 278 - 285. [Full Text] [PDF]

				A. Liede, B. Y. Karlan, and S. A. Narod Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature J. Clin. Oncol., February 15, 2004; 22(4): 735 - 742. [Abstract] [Full Text] [PDF]

				R. J. Brenner, J. N. Weitzel, N. Hansen, and P. Boasberg Screening-detected Breast Cancer in a Man with BRCA2 Mutation: Case Report Radiology, February 1, 2004; 230(2): 553 - 555. [Abstract] [Full Text] [PDF]

				C. J. van Asperen, M. A. Jonker, C. E. Jacobi, J. E. M. van Diemen-Homan, E. Bakker, M. H. Breuning, J. C. van Houwelingen, and G. H. de Bock Risk Estimation for Healthy Women from Breast Cancer Families: New Insights and New Strategies Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 87 - 93. [Abstract] [Full Text] [PDF]

				J. N. Weitzel, S. M. McCaffrey, R. Nedelcu, D. J. MacDonald, K. R. Blazer, and C. A. Cullinane Effect of Genetic Cancer Risk Assessment on Surgical Decisions at Breast Cancer Diagnosis Arch Surg, December 1, 2003; 138(12): 1323 - 1328. [Abstract] [Full Text] [PDF]

				M.-C. King, J. H. Marks, and J. B. Mandell Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 Science, October 24, 2003; 302(5645): 643 - 646. [Abstract] [Full Text] [PDF]

				D. J. Kaufman, T. H. Beaty, and J. P. Struewing Segregation Analysis of 231 Ashkenazi Jewish Families for Evidence of Additional Breast Cancer Susceptibility Genes Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 1045 - 1052. [Abstract] [Full Text] [PDF]

				B. A. Mincey Genetics and the Management of Women at High Risk for Breast Cancer Oncologist, October 1, 2003; 8(5): 466 - 473. [Abstract] [Full Text] [PDF]

				M de la Hoya, O Diez, P Perez-Segura, J Godino, J M Fernandez, J Sanz, C Alonso, M Baiget, E Diaz-Rubio, and T Caldes Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics J. Med. Genet., July 1, 2003; 40(7): 503 - 510. [Abstract] [Full Text] [PDF]

				P. A. Daly, C. Nolan, A. Green, W. Ormiston, N. Cody, T. McDevitt, B. O'hIci, D. Byrne, E. McDermott, D. N. Carney, et al. Predictive testing for BRCA1 and 2 mutations: a male contribution Ann. Onc., April 1, 2003; 14(4): 549 - 553. [Abstract] [Full Text] [PDF]

				S. M. Domchek, A. Eisen, K. Calzone, J. Stopfer, A. Blackwood, and B. L. Weber Application of Breast Cancer Risk Prediction Models in Clinical Practice J. Clin. Oncol., February 15, 2003; 21(4): 593 - 601. [Abstract] [Full Text] [PDF]

				H. T. Lynch, C. L. Snyder, J. F. Lynch, B. D. Riley, and W. S. Rubinstein Hereditary Breast-Ovarian Cancer at the Bedside: Role of the Medical Oncologist J. Clin. Oncol., February 15, 2003; 21(4): 740 - 753. [Abstract] [Full Text] [PDF]

				N D Kauff, P Perez-Segura, M E Robson, L Scheuer, B Siegel, A Schluger, B Rapaport, T S Frank, K Nafa, N A Ellis, et al. Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families J. Med. Genet., August 1, 2002; 39(8): 611 - 614. [Full Text] [PDF]